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Role of enhanced glomerular synthesis of thromboxane A2 in progres-
sive kidney disease. Normotensive rats of the Milan strain (MNS)
spontaneously develop focal glomerulosclerosis, In order to explore the
contribution of glomerular thromboxane (TX) A, synthesis to the
development of the disease, we have characterized the time course of
renal functional and biochemical changes, and their modification by
long-term treatment with a TX-synthase inhibitor. Oral administration
(150 mg kg from I to 14 months of age) of FCE 22178 suppressed
enhanced glomerular TXB2 production at all experimental times (mean
inhibition 80%) and proteinuria (varying between 27.1 and 73.0%) while
preserving renal blood flow and glomerular filtration rate. These effects
of TX-synthase inhibition were seen in the absence of any statistically
significant changes in systemic blood pressure. Moreover, FCE 22178
had no antihypertensive effects in hypertensive rats of the Milan strain
(MHS) nor in spontaneously hypertensive rats (SHR). Treatment also
prevented the age-related hypoalbuminemia and hyperlipidemia ob-
served in control MNS and significantly (P < 0.01) reduced glomerular
histologic damage, as demonstrated by light microscopy studies and
measurement of sclerotic area. We conclude that: 1) MNS rats provide
an animal model of long-lasting proteinuria characterized by an age-
related increase in glomerular TXB2 production paralleled by progres-
sive loss of renal structural integrity and function and by a secondary
dyslipidemia; 2) pharmacological inhibition of glomerular TX-synthase
attenuates the structural as well as the functional expression of kidney
disease, without a primary effect on systemic blood pressure. These
data are suggestive of an important modulating role of TXA2 in the
progression of MNS renal disease.
The Milan hypertensive strain (MHS) and the Milan nor-
motensive strain (MNS) are genetically related as they were
both developed from common ancestor Wistar rats by two-way
selection and inbreeding initiated in 1965 [1].
Several lines of evidence obtained both in vitro and in vivo
suggest that the kidney plays a pivotal role in the development
of hypertension in MHS [2, 3]. However, unlike the spontane-
ously hypertensive rats of the Okamoto strain (SHR), MHS
neither display renal lesions and proteinuria when hypertension
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is fully established, nor develop glomeruloscierosis with age. In
contrast, it was recently found [4] that the corresponding
normotensive controls, MNS, do develop focal glomeruloscler-
osis. Thickening of the glomerular basement membrane, capil-
lary lumen obliteration and pathological changes of podocytes
with extensive fusion of the foot processes are the prominent
features of the disease at 16 months; at this age marked
proteinuria occurs [41.
Similar age-dependent glomerulosclerosis has been described
previously in other normotensive inbred rat strains, although
usually at an older age [5]. Various factors have been proposed
to influence the occurrence of this disease such as sex, diet and
immunologic injury.
In the MNS, however, there is no evidence of immunologic
damage, as shown by immunofluorescence microscopy [4]. On
the other hand, preliminary studies have shown that glomeruli
isolated from adult MNS, produce significantly more thrombox-
ane (TX) A2 (measured as TXB2) in vitro than glomeruli from
age-matched MHS [6].
Several experimental [7—10] as well as clinical [11] forms of
glomerular disease share alterations in intrarenal arachidonate
metabolism, the most prominent feature of which is represented
by enhanced intrarenal production of TXA2.
This biochemical abnormality is often associated with pro-
teinuria, deteriorating renal function and progressive glomeru-
losclerosis, and suggests important effects of locally generated
TXA2 on glomerular arterioles and mesangial cells [12]. A
causal relationship between enhanced intrarenal TXA2 biosyn-
thesis and functional and structural changes has been estab-
lished in several experimental models through the use of
selective TX-synthase inhibitors [7—10, 13, 14]. Thus, the aims
of the present investigation were: 1) to further characterize the
development of renal disease in MNS, as a potential model of
heavy and persistent proteinuria and spontaneous age-related
glomeruloscierosis; 2) to characterize the spectrum of lipid
abnormalities accompanying progressive renal damage; 3) to
explore the role of glomerular TXA2 biosynthesis in this model
through serial biochemical measurements and long-term treat-
ment with a TX-synthase inhibitor.
447
448 Salvati et a!: TXA2 and kidney disease in rats
Our findings demonstrate a role for enhanced glomerular
TXA2 in contributing to renal functional and structural abnor-
malities in this model by showing that these can be substantially
prevented by pharmacologic blockade of TXA2 biosynthesis.
Methods
Experimental groups
Long-term studies. Male MHS and MNS rats of the F54
generation (42 animals from each strain), aged four weeks and
with body weight ranging between 70 and 80 g at the start of the
experiment, were used for this study. All rats received a
standard chow diet (Altromin MT, A. Rieper Vandois, Italy)
containing 0.3% Na and 23% protein, and had free access to
food and water throughout the experiment. The animals of each
strain were divided in two groups (N = 21).
Group 1 (MNS rats) and group 2 (MHS rats) were treated
with the selective inhibitor of TX-synthase, FCE 22178 [5,6-di-
hydro-7-( lH-imidazol- l-yl)-2-naphtalene-carboxylic acidi. FCE
22178 Na-salt (Batch A05001) was synthesized in Farmitalia
Carlo Erba Research Laboratories (Milan, Italy) [15]. The daily
dose of the drug was 50 mg kg' given orally by gastric tube
in the morning plus 100 mg. kg dissolved in the drinking tap
water. The concentration of the drug solution was adjusted
every second day according to water intake, in order to
maintain the dosage constant throughout the experiment. This
treatment schedule was found adequate, in preliminary exper-
iments, to maintain over 24 hours greater than 80% suppression
of circulating platelet TX-synthase activity (as reflected by
TXB2 levels generated in whole blood during clotting [16]).
Group 3 (control MNS) and group 4 (control MHS) received
saline, (0.2 ml. 100 g' body wt). All animals were treated as
above from 1 to 14 months of age. Water consumption, food
intake and body weight were measured daily between 8 and 10
a.m., just before drug administration by gastric tube.
Systolic blood pressure (SBP) measurements and urine col-
lections were performed bimonthly in all MNS and MHS rats.
At 4 weeks, and then at 2, 8 and 14 months of age six MNS
and MHS rats randomly chosen out of the initial number were
used for renal clearance studies, blood lipid and albumin
measurements. At the end of clearance studies, kidney speci-
mens were processed for light and electron microscopy and
glomeruli isolated for measurement of TXB2 production.
In order to investigate whether the effect of TX-synthase
inhibition on renal hemodynamics might be secondary to an
effect of the inhibitor on systemic arterial blood pressure, the
effect of FCE 22178 on this parameter was also studied in four
additional groups of rats of the Okamoto strain. Group 5
(spontaneously hypertensive rats, SHR, N = 21) and group 6
(Wistar Kyoto normotensive rats, WKY, N = 21) were given
FCE 22178 following the treatment schedule reported above;
group 7 (control SHR, N = 21) and group 8 (control WKY, N =
21) were given saline. All animals were four weeks old at the
beginning of the experiment.
Acute studies. The role of TXA2 in modulating renal hemo-
dynamics was further explored in separate groups of 12-month-
old MNS rats, that is, at a stage when their renal disease is fully
developed [4].
We compared the effects of an intravenous infusion of FCE
22178(10mg. kg' . hC'; N = 9) to that of the TXA2/PGH2
receptor antagonist BM 13,177 (3 mg . kg' . hr'; N = 6) on
the basis of the assumption that in presence of TXA2-synthase
inhibition, the accumulating PGH2 might act as TXA2 agonist.
The possible modulating role of enhanced vasodilator prosta-
glandin synthesis, caused by FCE 22178 through re-direction of
PGH2 metabolism, was studied in a further group of MNS (N =
6) receiving both compounds.
The selected infusion rate of FCE 22178 was able to com-
pletely (> 90%) inhibit TXB2 formation in whole blood during
clotting, as determined in preliminary experiments. Similarly,
the chosen infusion rate of BM 13,177 completely suppressed
the response to bolus injections of the TXA2 mimetic U46619 (2
sg. kg '). Control, saline infused, 12-month-old MNS (N = 5)
and normal Sprague-Dawley rats (3 months of age; N 8) were
included in the study for comparison.
Experimental procedures
Systolic blood pressure measurement and urine collection.
SBP was measured in conscious rats of the Milan and of the
Okamoto strains bimonthly (first measurement at 4 weeks of
age, before starting the treatment) by the indirect tail-cuff
method using a W+W BP recorder (Basile, Varese, Italy) after
prewarming the animals at 29°C for 10 minutes. Each value
represents the mean of at least five consecutive readings.
Urine collections were made one week after SBP measure-
ment. The animals were placed in metabolic cages with free
access to food and water. After an adaptation time of three
days, two consecutive 24-hour urine samples were collected
into ice cooled containers.
Total urinary protein concentration was measured by the
Biuret method (Total protein, Boehringer M., Mannheim, FRG)
and the excretion rate expressed as mg . 24 hr'.
For each parameter, the mean of the two 24-hour collection
periods was calculated and used for further calculations and
statistics.
Renal clearance in chronic studies. Under light halothane
anesthesia the right carotid artery and the left jugular vein were
cannulated with a polyethylene tube (PE 50) for blood sampling
and infusion, respectively. Glomerular filtration rate (GFR) and
renal plasma flow (RPF) were measured four hours after sur-
gery in conscious rats according to the constant infusion
method [171. Briefly, after a priming dose (0.4 ml . 100 g1 body
wt) of 12 zCi . kg '251-hippuran, (Amersham mt. plc,, Buck-
inghamshire, UK) and 24 Ci . kg' 51Cr-EDTA (Amersham),
a maintenance infusion of 18 sCi . kg . hr of '251-hippuran
and 36 Ci . kg . hr' of 51Cr-EDTA were delivered into the
venous catheter by a syringe (Hamilton Bonaduz AG, Bonaduz,
Switzerland) fitted into an infusion pump (model 341, Sage
Instruments, division of Orion, Cambridge, Massachusetts,
USA) for three hours. Three duplicate samples of plasma (20 s1)
were collected at 20 minute intervals starting after 90 minutes of
equilibration and counted in a Beckman gamma 8000 Counting
system (Beckman Instruments Inc. Irvine, California, USA) for
20 minutes. GFR and RPF were calculated by standard formu-
lae. At the end of the clearance studies, the animals were
anesthetized by intraperitoneal injection of Na pentobarbital (45
mg. kg') and their kidneys were removed; specimens were
obtained for histologic examination. The remaining tissue was
immediately frozen and stored at —80°C, until processed for the
isolation of glomeruli in order to assess their ability to synthe-
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size TXA2 ex vivo. Preliminary experiments showed that freez-
ing does not alter glomerular TXB2 production (data not
shown).
Renal clearance in acute studies. Renal function in conscious
12-month-old MNS rats was measured by the clearance of
inulin (C1) (E. Merck, Darmstadt, FRG) and p-aminohippuric
acid (CPAH) (Sigma Chemical Co., St. Louis, Missouri, USA).
Rats were chronically implanted with indwelling arterial and
venous catheters 48 hours in advance under halothane anesthe-
sia for blood collection and drug infusions; the day of the
experiments a large polyethylene tube (PE90) was inserted into
the bladder through a small suprapubic incision for urine
collection.
For comparison, control, three-month-old Sprague-Dawley
rats were similarly prepared.
Two hours after surgery, a priming i.v. dose of 5% inulin and
0.2% PAH was given, followed by a slow infusion of saline (2
ml . hr 1) containing sufficient inulin and PAH to maintain,
both in normal and nephrotic rats, their plasma levels constant
(0.8 to 1.3 mglml for inulin and 0.005 to 0.008 mg/mI for PAH,
respectively).
A 60-minute equilibration period was allowed, and a baseline
clearance period was obtained (60 mm), then animals received
the different i.v. infusions (0.5 ml. hr'). Four 60-minute
clearance periods were then performed. Plasma and urine inulin
and PAH were determined using colorimetric standard tech-
niques [18, 19]; C1, and CPAH were corrected per gram of wet
kidney weight.
Measurement of serum lipids and serum albumin. Blood
samples were obtained in fed conditions from the venous
catheter of MNS and MHS rats undergoing clearance studies at
1, 2, 8, 14 months of age. Serum total cholesterol, triglycerides
and phospholipids were determined by enzymatic colorimetric
methods (Clinicals, Carlo Erba, Milan, Italy) using a Kem-O-
Mat 2 autoanalyzer (Coulter Kontron, Milan, Italy). Serum
albumin was measured by rocket immunoelectrophoresis [20] in
control and treated 14-month-old MNS. Rat albumin (Cohn
fraction V) purchased from Sigma Chemical Co. was used as a
standard for albumin determinations.
Glomerular isolation and incubation. Glomeruli were iso-
lated as previously described [9] with minor modifications.
Briefly, the renal capsules were removed, the cortex was
separated from the medulla and finely minced to a paste-like
consistency. All subsequent preparative steps were performed
at 4°C.
The homogenate was gently passed through a 106 m stain-
less steel sieve which excluded the tubules and then washed
with Krebs-Ringer phosphate buffer (KRB, 120.3 m NaCI, 4.8
mM KCI, 1.2 m'vi MgSO4, 15.6 mrvi, pH 7.4) over a 75 m sieve
which retained the glomeruli. The glomeruli were suspended in
ice cold KRB and allowed to settle spontaneously. The super-
natant was discarded and the pellet resuspended in the same
buffer solution. This washing step was repeated two more
times. The purity of isolated glomeruli was determined micro-
scopically by counting the number of glomerular and non-
glomerular particles suspended in a given volume. The final
pellet consisted of decapsulated glomeruli with less than 5%
tubular contamination. For direct radioimmunoassay (RIA)
measurements of TXB2 isolated glomeruli were centrifuged at
150 x g for five minutes, resuspended in 1 ml KRB supple-
mented with 2.57 mi CaCl2, and incubated for 60 minutes in a
Dubnoff shaking water bath at 37°C. Incubation was stopped by
centrifugation at 3,000 x g for five minutes and the supernatant
of each tube was collected and frozen until assayed for TXB2.
Glomerular protein concentration was determined according to
the method of Lowry et a! [21].
Glomerular TXB2 radioimmunoassay. TXB2, the stable
breakdown product of TXA2, was assayed in glomerular super-
natants at a final dilution of 1:150. RIA was performed as
previously described [13]. Briefly, 5,000 dpm of 3H-TXB2 (113
Ci• mmol ')and an aliquot of specific rabbit antiserum (final
dilution 1:250,000) sufficient to bind 40 to 50% of the tritiated
compound were incubated for 16 to 24 hours at 4°C in a final
volume of 1.5 ml for each assay tube. Separation of antibody-
bound from free-labeled antigen was achieved by rapid addition
of 0.1 ml of human prostaglandin-free plasma and 0.1 ml of a
charcoal suspension (50 mg. m1') and subsequent centrifuga-
tion at 4°C. The supernatant solution containing antibody-
bound TXB, was decanted directly into 8 ml of Instagel
(Packard Instrument Co. Inc., Downers Grove, Illinois, USA).
Radioactivity of samples was counted in a liquid scintillation
counter (LS 1800 model, Beckman Instruments, Irvine, Cali-
fornia, USA). Results were expressed as ng. mg' protein. The
smallest concentration of TXB2 that could be measured with
95% confidence was 2 pg. ml. The cross reactivity at 50%
displacement of other arachidonate metabolites was as follows:
2,3-dinor-TXB2, 10.5%; 6-keto-PGF1 ,, <0.006%; PGF2,
0.023%; PGD2, 0.02%; PGE2, 0.007%; arachidonate, <0.004%.
Interassay and intraassay variability, evaluated by assays of
several glomerular preparations, averaged 4% and 3%, respec-
tively, over a range of concentrations from 1 to 100 pg .mF'.
Validation of RIA measurements was obtained by several inde-
pendent criteria: dilution and recovery studies, comparison among
multiple antisera, characterization of the chromatographic pattern
of distribution of the extracted thromboxane-like immunoreactiv-
ity on thin layer chromatography and comparison with gas chro-
matographic-mass spectrometric determinations. These tech-
niques are described in detail elsewhere [11].
Morphology. The kidneys from 82 out of 84 animals (42 MHS
and 40 MNS, both treated and untreated) were processed
according to following schedule: after sacrifice, 2-mm thick
slices from each kidney were postfixed in neutral 10% formalin,
dehydrated and embedded in metacrylic resin (Historesin,
LKB, Bromm, Sweden); 0.5 sm sections were stained with
hematoxylin/eosin (H/E), periodic acid Schiff (PAS) and peri-
odic acid Schiff + methenamine (PASM), for light microscopy.
Light microscopic studies included histopathological obser-
vations with emphasis on the degree of glomerular involvement
by sclerosis.
Sclerosis was defined as an increase in mesangial matrix, or
segmental substitution of the capillary tuft by fibrosis, or
adhesion between visceral and parietal layers of epithelial cells,
with various degrees of capillary lumen obliteration. A PAS
stained, 5-sm thick coronal section from each animal was
blindly estimated by two independent observers and the degree
of glomerulosclerosis was semiquantitatively graded from 0
(absent) to 4 (global hyalinosis). Grade 1 to 4 was given when
the glomerular area involved was 25%, 50%, 75% and 100%,
respectively. The extent of glomerulosclerosis was estimated as
the percent of sclerotic area over the total glomerular area; for
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example, if 25 of 110 glomeruli had a lesion of 1 + and 10 of 110
had a lesion of 3+ the final percent of affected area in this
sample would be: [(25 x 1/4) + (10 x 3/4)] x 100/110 = 12.5%.
The adopted procedure is a modification of that proposed by
Raij, Azar and Keane [22] and used by Yoshida, Fogo and
Ichikawa [231.
Electron microscopy studies were performed in a subset of
the whole population; control and treated rats of each strain
were selected as reported:
Experimental population (58 animals; C = control, T =
treated) used for ultrastructural studies divided by strain and
age:
MNS: 1 month (3C); 2 months (2T, lC); 8 months (6T,
SC); 14 months (5T, 6C).
MHS: 1 month (3C); 2 months (2T, lC); 8 months (6T,
6C); 14 months (6T, 6C).
Tissue blocks, I to 2 mm thick, obtained from the renal
cortex were immersed for two hours in 2.5% glutaraldehyde,
0.13 M phosphate buffer pH 7.2, washed in buffer, post-fixed in
0s04, ethanol dehydrated and embedded in Epon 812.
For each animal, three to five semi-thin sections, obtained
from three different blocks, were collected onto a histologic
slide and stained with 1% toluidine blue.
From each slide four to five glomeruli were selected under
light microscopy, among those without apparent glomerulo-
sclerosis. Accordingly, ultra-thin sections, including the se-
lected glomeruli, were cut, uranylacetate and lead citrate
stained and observed with an electron microscope (ElmiSkop
1A, Siemens, Berlin, FRG). Interstitial fiogosis was graded
from 0 (absent) to 3+ (severe).
Statistical analysis
Results are reported as mean SEM, except glomerular TXB2
levels that are mean SD. Data were analyzed by analysis of
variance using Duncan's test for multiple comparison or by
unpaired Student's t-test for single comparisons [24],
The correlation between glomerular TXA2 production and
proteinuria was evaluated using a polinomial regression model
[25].
Results
Systolic blood pressure and urine measurements
Values of SBP in control and treated MNS rats are reported
in Table 1. SBP rose significantly from four to six weeks of age
in both control and FCE 22178-treated animals, and in both
groups remained in the range of age-matched normotensive rats
of the Okamoto strain (WKY) throughout the study. In fact the
pattern of SBP in MNS rats was indistinguishable from that in
WKY rats (Fig. 1). Similarly, in MHS rats, treatment with the
TX-synthase inhibitor did not alter the time course of hyper-
tension development, nor did it reduce blood pressure in adult
hypertensive animals to any statistically significant extent (data
not shown). Consistently with the lack of a primary antihyper-
tensive effect of FCE 22178, the drug did not affect the pattern
of development of hypertension in SHR rats (Fig. 1).
Data on body weight, water intake and urine volume of MNS
and MHS rats are given in Table 2. There were no statistically
significant differences in the initial body weight of rats of the
Age N
SBP mm Hg
MNS
control
MNS
treated
4 weeks
6 weeks
2 months
4 months
6 months
8 months
12 months
14 months
21
18
18
12
12
12
6
6
121.4 2.4
135.5 1.9
134.! 1.7
137.9 2.9
142.1 1.6
137.9 3.0
144.1 2.1
150.0 3.1
118.8 3.1
133.8 2.1
133.0 2.2
143.7 2.1
139.1 3.0
145.8 2.2
138.3 6.2
150.1 3.2
P > 0.05 for all comparisons control vs.
Age, months
Fig. 1. Age dependent changes of systolic blood pressure (SBP) mea-
sured by tail cuff method in conscious, SHR (control •, treated0); and
WKY (control U, treated LI) rats. Treatment with FCE 22178 was
performed as reported in the methods. Means SEM are reported. The
number in parentheses represents the number of animals for each group
at different ages.
two strains, nor in their weight gain up to eight months of age,
when body weight of MHS was significantly (P < 0.05) higher
than that of MNS by approximately 20%.
FCE 22178-treated animals showed slightly lower body
weights at 8 and 14 months compared to the corresponding
controls.
Young (1 month old) MHS rats had a significantly higher
urine volume with respect to matched MNS, but this difference
disappeared when hypertension developed, as previously re-
ported [1]. On the other hand, 14-month-old control MNS
showed a markedly increased urine volume as compared to
matched MHS (41.7 5.0 vs. 11.4 0.8 ml . 24 hC'; P <
0.01).
MNS water intake was increased in parallel. MNS rats
receiving FCE 22178 had significantly lower water intake and
urinary volumes than MNS receiving vehicle alone, at all
experimental time points. The reduced urine volume might be
Table 1. Systolic blood pressure (SBP) of control and FCE 22178-
treated rats of the Milan normotensive strain (MNS) at different ages
Data are mean 5EM;
treated.
260 —
240 —
220 —
:1 200—
180—
ci,
160 —
140 —
120 —0-
1 2 4 6 8 10 12 14
(21)(18) (12) (12) (12) (6) (6) (N)
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Table 2. Body weight, water intake and urine volume of control (C) and FCE 22178-treated (T) rats of the Milan normotensive strain (MNS)
and of the Milan hypertensive strain (MHS) at different ages
1 Month 2 Months 8 Months 14 Months
MNS MHS MNS MHS MNS MHS MNS MHS
Parameter (N = 21) (N = 21) (N = 18) (N = 18) (N = 12) (N 12) (N = 6) (N 6)
Body wt g C 101.5 3.3 96.2 1.7 261.0 4.2 268.5 5.0 432.2 6.9° 515.3 9.8 465.2 lo.sa 549.2 19.9
T 105.3 3.0 109.0 2.0 256.2 4.1 264.8 4.9 418.3 6.7 487.1 14.6 433.0 6.1 504.8 13.8
1420 intake
ml/24hr
C 17.1 0.6 18.0 0.7 24.1 0.8
C
24.8 0.7 23.7 1.3d 24.4 1.2 47.1 4.0d 24.6 1.0
T 17.9 0.8 20.7 0.8 21.5 0.5 24.6 0.6 17.8 1.1 21.3 1.1 28.1 5.0 22.7 1.0
Urine C 4.01 0.la 5.90 0.4 8.43 0.3 8.82 0.4 14.1 0.7 13.5 0.7 41.7 50b 11.4 0.8
volume C d d
ml/24 hr T 4.69 0.1 6.50 0.3 6.81 0.2 8.82 0.3 10.2 0.4 12.0 0.7 18.8 4.1 12.8 0.7
Data are means SEM.
a p < 0.05, b P < 0.01 control MNS vs. control MHS
p < 005 d P < 0.01 control vs. treated by Duncan's test
Data are means SEM.
ap < 0.05; bp < 0.01 MNS vs. MHS by Duncan's test
due to an improvement in concentrating capability in treated
MNS as a consequence of a lower degree of tubular atrophy as
suggested by histologic findings (see below). Treatment did not
modify these parameters in MHS. Food intake was normal in
both control and treated rats of the two strains. In addition, we
did not observe any abnormal behavior, nor diarrhea.
Total urinary protein excretion of control MNS and MHS rats
from 1 to 14 months of age, is detailed in Table 3. In MNS
marked proteinuria developed after the fourth month, becoming
massive by 14 months of age (625.3 94.1 mg. 24 hr');
however, even young MNS had a significantly higher protein
excretion than MHS rats at the beginning of the experiment (3.5
0.4 vs. 1.9 0.3 mg . 24 hr, P < 0.05). On the other hand,
unlike other hypertensive strains, proteinuria did not develop in
old hypertensive MHS (24.2 2.5mg. 24 hr', at 14 months of
age).
The high urinary protein excretion of 14-month-old MNS was
paralleled by a lower plasma concentration of albumin (16.8
2.3 mg. ml, N = 5) as compared to normal values in
normotensive rats of that age (mean value 35.0 0.08
mg ml ') as shown by Berg [261. Treatment with the TX-
synthase inhibitor reduced, but did not abolish, the proteinuria
of MNS rats. Total protein excretion (expressed in mg. 24
hr ') of treated MNS was significantly lower than that of
control MNS after the fourth month of age (Fig. 2). The extent
of reduction was remarkably constant throughout the study,
ranging from 50% at 6 months to 53% at 14 months of age (291.7
Fig. 2. Twenty-four-hour protein excretion of MNS (control U, treated) and MHS (control I, treated 0) at dJferent ages. Treatment with
FCE 22178 was performed as described in the methods. Means SEM
are reported; the number in parentheses represents the number of
animals for each group at different ages. ** P < 0.01 by Duncan's test
in comparison to age matched controls.
55.4 in treated vs. 625.3 94.1 mg. 24 hC' in control rats at
14 months of age).
Treatment with the TX-synthase inhibitor was also associ-
ated with significantly higher plasma albumin levels, as mea-
sured at 14 months (from 16.8 2.3 in control to 25.3 3.2
mg. m11 in treated MNS, P < 0.01, N = 5).
FCE 22178 had no effect on total protein excretion of MHS
rats (Fig. 2).
Renal clearance in chronic and acute studies
Figure 3 depicts the age-related changes in renal hemodynam-
ics measured in MNS and MHS rats during the long-term study;
in control MNS both RPF (measured as '251-hippuran clear-
ance) and GFR (measured as 51Cr-EDTA clearance) were
significantly decreased at 8 months, and markedly reduced at 14
months of age when compared to basal values: RPF from 4.0
0.2 to 1.7 0.3 ml . min' . g kidney weight (P <0.01); GFR
from 1.4 0.06 to 0.5 0.1 ml. min . g' kidney wt, (P <
0.01). In contrast, both parameters remained remarkably stable
during the entire life span of MHS rats. Therefore both RPF and
Table
normotensive
3. Urine protein excretion in control rats of the Milan
strain (MNS) and of the Milan hypertensive strain
(MHS) as a function of aging
Age
Urine protein mg 24 hr'
N MNS MHS
4 weeks
6 weeks
2 months
4 months
6 months
8 months
12 months
14 months
21 3.5 0.4° 1.9 0.3
18 21.9 19b 9.1 0.7
18 40.1 1.6° 32.1 1.7
12 122.8 42b 38.3 4.7
12 288.3 306b 22.2 1.8
12 385.2 37.7k' 24.5 1.8
6 471.9 514b 22.1 3.5
6 625.3 94.l' 24.2 2.5
640
560
480
400
320
240
160
80
0
Age, months
6 8 12 14
(12) (12) (6) (6) (N)
6
0)
4
-
2
LI..0 0
Fig. 3. Age-related changes of renal plasma flow
(RFF), glomerular filtration rate (GFR) and 24-
hours urinary protein excretion expressed per ml
of51Cr-EDTA clearance in control (U) and
treated (U) MNS (A) and MHS rats (B).
Treatment with FCE 22178 was performed as
reported in the methods. Means SEM of 5 to 6
animals are shown. * P < 0.05; ** P < 0.01 by
Duncan's test in comparison to age-matched
controls.
GFR, which were similar in the two groups at the beginning of
the study, became significantly lower in MNS than in MHS, at
8 and 14 months. Treatment with the TX-synthase inhibitor
substantially preserved renal function in MNS rats; RPF didnot
fall with age, remaining significantly (P < 0.01) higher than in
controls both at 8 and 14 months of age (at 14 months 3.3 0.08
in treated vs. 1.7 0.3 ml. min' . g kidney wt in control
MNS). Similarly, FCE 22178 largely prevented the decrease in
GFR at the same experimental time points (at 14 months 1.3
0.2 in treated vs. 0.5 0.1 ml. min .g kidney wt in control
MNS, P < 0.01). When taking into account these differences in
GFR, the effect of the inhibitor on glomerular permeability to
proteins appears even more pronounced than reflected in Figure
2. Thus, total protein excretion of the animals undergoing
clearance studies (expressed per milliliter of GFR), was re-
duced by approximately 75% at 14 months in treated MNS with
respect to age-matched controls (Fig. 3). In MHS rats, on the
contrary, RPF, GFR and total protein excretion were similar in
control and treated animals at all experimental time points.
In acute studies, RPF and GFR of 12-month-old control MNS
were significantly lower (P < 0.01) as compared to those of
normal, 3-month-old Sprague-Dawley rats (2.9 0.7 vs. 5.8
1.0 and 0.2 0.06 vs. 1.6 0.3 ml . min . g' kidney wt,
respectively). Saline infusion had no effect on these parameters
in MNS. Thromboxane synthesis inhibition with FCE 22178
and/or thromboxane receptor antagonism with BM 13,177 failed
to modify acutely RPF and GFR in MNS rats (Table 4).
Proteinuria was also similar in control and treated MNS both
under basal conditions and four hours after saline or drug
infusion (data not shown).
Measurement of serum lipids
Serum cholesterol, phospholipids and triglycerides were not
significantly different in one-month-old MHS and MNS rats and
were in the normal range for rats of that age [27] (Fig. 4).
No age-related increase in serum lipids was detected in
Table 4. Renal hemodynamic parameters in 12-month-old rats of the
Milan normotensive strain (MNS) treated with saline (0.5 ml h'),
FCE 22178 (10 mg kg h), BM 13,177 (3 mg kg hr')
or both
CPAH ml min' g'
kidney wt"
C,, ml min'
kidney wt'
Drug Drug
Control infusion Control infusion
Group N period (4th hr) period (4th hr)
Normal rats 8 5.8 1.0 — 1.6 0.3 —
MNS
Saline 5 2.9 0.7 2.3 0.6 0.19 0.06 0.32 0.09
FCE 22178 9 2.1 0.5 3.7 1.3 0.20 0.06 0.35 0.13
BM 13177 6 2,7 0.7 2.7 0.5 0.17 0.04 0.18 0.07
BM 13177 + 6 2.6 0.5 2.6 0.6 0.27 0.05 0.36 0.1
FCE 22178
Data are means SEM.
a p-aminohippuric acid clearance
b inulin clearance
control MHS rats. On the other hand, serum lipids of MNS
showed a progressive increase with age and reached very high
levels at 14 months: cholesterol (218.0 30.0 mg . d1'),
phospholipids (256.8 26.4 mg . d1') and triglycerides (399.6
104.7 mg dl—') were all significantly (P < 0.01 by unpaired
i-test) elevated when compared to one month values as well as
to measurements performed in age-matched MHS rats.
FCE 22178 had no effect on serum lipids of MHS, but largely
prevented the age-related increase in cholesterol, phospholipids
and triglycerides of MNS rats (117.8 3.9; 160.2 15.1 and
169.3 26.1 mg• d1', respectively, at 14 months).
Glomerular TXA2 synthesis
Figure 5 depicts the ex vivo glomerular production of TXA2,
(measured as TXB2, 6 hours after the last treatment) in control
and FCE 22178-treated MNS and MHS rats at 1, 2, and 14
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months of age. Other arachidonate metabolites were not mea- 8
sured as data on the glomerular synthesis of PGE2 and PGI2, at
different ages, were already available from previous studies in
both strains [28].
As early as the second month of life, glomerular synthesis of
TXA2 was increased several-fold in MNS rats. A 12-fold
increment was measured at 14 months (from 0.47 0.1 at 1
month to 5.7 0.9 ng. mg prot . hr, P < 0.01 by unpaired
t-test).
Glomerular TXB2 production increased significantly also in
MHS though only at 14 months of age and to a lesser extent
than in MNS (from 0.49 0.1 at I month to 1.8 0.2 ng. mg'
prot. hour', at 14 months, P < 0.01).
MNS rats receiving the TX-synthase inhibitor showed mark-
edly reduced glomerular TXB2 production (80%) at both exper-
imental time points. A statistically significant reduction in
glomerular TXB2 production was also observed in treated MHS
rats at 14 months.
To assess the relationship between ex vivo glomerular TXA2
synthesis and glomerular injury, TXB2 levels were correlated
with urinary protein excretion and GFR in both control and
treated MNS. A statistically significant correlation (r = 0.72, N
= 39, P < 0.01) was found between glomerular TXB2 produc-
tion and urinary protein excretion (Fig. 6). Moreover, an
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Fig. 4. Total serum cholesterol, phospholipids and triglycerides in
control (0) and treated () MNS and MHS rats at different ages.
Treatment with FCE 22178 was performed as reported in the methods.
Means SEM of (N) animals are shown. * p < 0.05; ** P < 0.01 in
comparison to age matched saline-treated control rats by unpaired
t-test. Number of animals ofeach group is reported in the 1st series of
bars.
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Fig. 5. TXB2 production by isolatedglomeruli (N = 6)from control (U)
and treated (0) MNS and MHS rats at different ages. Treatment with
FCE 22178 was performed as reported in the methods. Data are shown
as means 5D; ** P < 0.01 by unpaired t-test in comparison to age
matched controls.
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Fig. 6. Correlation between the presacrfice 24-hours urine protein
excretion (proteinuria . 24 h') and the post-sacrUlce ex vivo glomeru-
lar TXB2 synthetic rate in MNS rats at dUferent ages. Control (•) and
treated (A) rats are plotted together. Treatment with FCE 22178 was
performed as reported in the methods. N = 39; r = 0.72; P < 0.01.
inverse correlation (r =
—0.63, N = 39, P < 0.01) was found
between TXB2 synthetic rate and GFR (51Cr-EDTA clearance;
not shown).
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Table 5. Percentage sclerotic glomerular area in rats of the Milan
normotensive strain (MNS) and in rats of the Milan hypertensive
strain (MHS) at 8 and 14 months of age
Age
months
MNS MHS
Control Treated Control Treated
8 30.5 31b 17.5 l.6 4.3 0.9 4,6 0.8
(126) (148) (132) (159)
14 46.1 39b 34.2 4,7a 8.4 1.6 9.9 1.1
(140) (149) (165) (190)
The mean number of glomeruli measured in each kidney are reported
in parentheses. Data are means SEM (N = 5 to 6 kidneys per group).
The % sclerotic area was calculated on the basis of a sclerotic index as
reported in Methods.
P < 0.01 vs. corresponding control (MNS) valuesb P < 0.01 vs. corresponding control MHS
Morphology
Light microscopy. No appreciable histologic abnormalities
were observed in one and two month old treated as well as
untreated MNS. Lesions observed in 8- and 14-month old
animals included focal glomerular sclerosis and hyalinosis, with
a segmental or global pattern. The capillary lumina were often
narrowed or even obliterated by PAS and PASM+ material,
that was preferentially located in the mesangial compartment.
Tubules showed atrophy of epithelial cells with occasional
proteinaceous casts in the lumen. Percentage sclerotic area,
calculated from the sclerosis index as reported in the methods,
is shown in Table 5.
MNS had a significantly higher (P < 0.01) percent sclerotic
area at 8 months of age (range 22 to 37%; N = 6) as compared
to MHS (range 2 to 8%; N = 6). This difference was more
marked at 14 months (range 37 to 61%; N = 6 vs. 4 to 14%; N
6). Treatment with FCE 22178 significantly (P < 0.01)
reduced the percent of sclerotic area in MNS at both expen-
mental time points, but was without any measurable effect in
MHS. At variance with MNS, 8-month-old MHS showed a
moderate thickening of the media of the interlobular arteries
which was slightly more pronounced at 14 months. This param-
eter was not modified by treatment.
Electron microscopy. In the present preliminary study the
ultrastructural investigation has been mainly focused on the
glomerular pattern of control rats of the two strains, and
differences between treated and untreated animals were more
qualitative than quantitative.
At 28 days, which was assumed as the basal condition, the
glomerular structure of MNS rats did not show any significant
abnormality. At two months of age, the glomerular pattern was
unmodified in both treated and untreated animals, with only
occasional focal areas of homogeneous thickening of the lamina
densa (LD) of the glomerular basement membrane (GBM). At 8
and 14 months of age, the ultrastructure of the glomerular
components showed appreciable abnormalities definitely more
pronounced in older animals. A frequent finding observed in
almost all glomeruli of untreated animals was a generalized
flattening and fusion of foot processes, with consequent col-
lapse of the epithelial cell body over the GBM (Fig. 7). On the
contrary, in the glomeruli of FCE 22178-treated animals, epi-
thelial cells showed only moderate aspects of foot process
fusion and in some cases the morphology was considerably well
preserved (Fig. 8).
Other common findings more pronounced and frequent in
untreated than in treated animals were: a) villosity with produc-
tion of abundant irregular cytoplasmatic projections protruding
into the capsular space (Fig. 7 inset); b) increased number of
particularly electron-dense lysosomes and presence of large
vacuoles and wide electronlucent blebs, surrounded by a thin
rim of cytoplasm (Fig. 7); and c) presence of considerable
amounts of filamentous material, morphologically consistent
with actin, often arranged at the periphery of the cytoplasm. In
most severe cases, focal aspects of the detachment of
podocytes from the GBM were observed (Fig. 9). The latter
finding was absolutely exceptional in treated MNS.
Finally, the mesangial matrix appeared markedly increased
as a consequence of the deposition of basement membrane-like
material, which often caused obliteration of the capillary lumen.
This feature was definitely less frequent and less pronounced in
FCE 22178-treated animals.
No appreciable presence of platelets was detected in any of
the examined glomeruli. In MNS rats interstitial flogosis was
modest (1+) at 8 months and slightly higher (1+12+) at 14
months; the degree of flogosis was not modified by treatment
with FCE 22178.
Discussion
The results of the present study show that the renal disease of
MNS rats is characterized by persistent proteinuria, hypoalbu-
minemia and hyperlipidemia, and a progressive impairment of
renal function. An interesting finding was that arterial blood
pressure remained at normotensive levels throughout the MNS
life span, unlike other models of renal damage with similar
pathologic features [29, 30]. This observation would tend to
minimize any role for systemic hypertension in the develop-
ment of glomerular damage in MNS. In this series of experi-
ments we did not measure glomerular capillary pressure (P5w)
and therefore we cannot exclude glomerular hypertension in the
late stages of the disease. However, previous studies showed
that in younger animals (3 months of age) P5 was significantly
(P < 0.01) lower in MNS as compared to MHS rats [31].
We found sclerotic glomerular changes after the eighth month
of age. Ultrastructural studies of nonsclerotic glomeruli showed
thickening of the GBM and an age related increase of mesangial
matrix which appeared to be strictly related to the structural
modifications of epithelial cells. Flattening and fusion of the
foot processes, as well as formation of blebs and of electron-
dense lysosomes. together with the frequent detachment of the
cells from the GBM might be related to the massive leakage of
proteins through the glomerulus [32].
These data confirm and extend previous observations of
Brandis et al [4], who first described glomeruloscierosis and
proteinuria in MNS rats. The absence of rat complement and
IgG in the glomeruli led the authors to suggest that an immu-
nologic mechanism is unlikely to be responsible for this glomer-
ulopathy. We also extended preliminary observations of an
age-related increase in glomerular synthesis of TXA2, as de-
tected ex vivo by the production of the stable hydrolysis
product, TXB2 [28]. Other experimental models of non-immune
as well as immune renal damage show abnormalities in the
intrarenal metabolism of arachidonate [7—10, 33—35]. However,
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Fig. 7. Untreated MNS rat, 14 month old: (2200x). Glomerular epithelial cells (E) show electrondense lysosomes, a bleb (B), flattening and fusion
of foot processes (arrows). INSET: high magnification of the same picture showing villosity of an epithelial cell.
Fig. 8. Treated MNS rat, 14 month old: (2200x). Note the preservation of the foot processes compared to Fig. 7.
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Fig. 9. Untreated MNS rat, 14 month old: (5800x). Arrows point to a
focal detachment of the epithelial cell surface from the GBM.
if we exclude examples of autoimmune kidney disease, such as
the munne model of lupus nephritis [36], the MNS glomerulo-
sclerosis is the first example, to our knowledge, of a spontane-
ous, non-immune, genetically determined renal disease in the
rat, characterized by a slow onset and long lasting proteinuria,
where a role for intraglomerular TXA2 production has been
established on the basis of biochemical measurements and
inhibitor trials. In this study, in fact, we found that the oral
administration of FCE 22178, an imidazole-analogue inhibitor
of TXA2-synthase, slowed the progression of MNS renal dis-
ease, Protein excretion was markedly decreased by FCE 22178;
the reduction of proteinuria did not appear to be a consequence
of a reduction in tubular load as GFR was not decreased by the
drug. On the contrary, GFR and RPF were significantly higher
in treated animals than controls, at both 8 and 14 months of age,
and were not significantly different from baseline values. On the
basis of these data, it is likely that FCE 22178 did not decrease
P and actually increased glomerular perfusion and filtration in
this animal model; nevertheless the percent of sclerotic glomer-
ular area was less in treated as compared to control rats. These
data are consistent with the findings of Purkerson et al, who
have shown that a TXA2-synthase inhibitor (OKY 1581) ame-
liorates the progressive kidney disease in the rat model of
reduced renal mass in the face of a further increase in glomer-
ular hyperfiltration [101. However, in that study, treatment with
OKY 1581 was also associated with a fall in systemic blood
pressure, an effect likely contributing to the improvement in
renal histology.
In our study, the beneficial effects of FCE 22178 on renal
function and structural integrity were not associated with any
significant change in systemic blood pressure, thereby implying
a largely intrarenal mechanism of action. As we did not measure
glomerular hemodynamics, one might speculate that FCE 22178
normalized intraglomerular capillary pressure, possibly in-
creased in old MNS. Alternatively, MNS might behave like
puromycin-treated rats, in which gc remains normal in spite of
reduced renal function [37]. In that model, TXA2-synthase
inhibitors have been shown to exhert beneficial effects on renal
function and proteinuria without modifying P8 [38, 39].
Moreover, our results in control MNS are at variance with
the findings in rats with subtotal nephrectomy in that a lower
degree of glomerular sclerosis was found. This difference might
reflect the additional glomerular damage induced by systemic
hypertension in the reduced renal mass model. On the other
hand, Yoshioka et al [40] have recently shown that in the
subtotal nephrectomy model, nephrons without glomeruloscier-
osis (that is, with intact structure at light microscopy) often had
the highest filtration rate of albumin. Thus, proteinuria after
subtotal nephrectomy originates largely from glomeruli with
minimal structural abnormalities. These observations have
raised the possibility that in chronic renal diseases, the reduc-
tion in proteiriuria seen after a variety of therapeutic measures,
including TX-synthase inhibition, may reflect their functional
effect on the relatively intact glomeruli rather than their struc-
ture-sparing effect on severely damaged glomeruli, which con-
tribute little to the proteinuria [401. Our present results are
consistent with such a possibility, in showing up to 75%
reduction in proteinuria in the face of only a 26% sparing in
sclerotic area.
Our results do not address the questions as to the cellular
origin of enhanced glomerular TXB2 production and to the
molecular transduction of this biochemical abnormality into
changes of glomerular function and structure. However, inter-
stitial flogosis was also modest in the histologic sections from
old animals (14 months), whereas enhanced glomerular produc-
tion of TXB2 was also present in younger rats. No platelet
deposition could be demonstrated.
These observations point to native glomerular cells as the
main source of TXA2. Yet, we cannot rule out a contribution to
increased glomerular TXA2 by infiltrating cells in a late phase of
the renal disease. Therefore a possible role of intraglomerular
TXA,-dependent platelet activation in this particular disease
process, as suggested by Purkerson et al [10, 41] in the remnant
kidney model, remains to be investigated with appropriate
pharmacologic tools.
Moreover, the genetic determinant(s) responsible for the
age-related increase in TXA2 synthesis remains to be defined.
Because enhanced protein excretion preceded any detectable
increase in glomerular TXB2 production and profound suppres-
sion of the latter did not completely prevent development of the
disease, we are inclined to suggest that TXA2 represents an
important mediator amplifying glomerular injury in response to
a variety of mechanisms [42—44] and not a primary determinant
of the disease. Preservation of RBF and GFR in animals treated
with FCE 22178 is consistent with the effects of similar inhibi-
tors of TX-synthase in other rat models [7, 9, 13] and suggests
important effects of locally generated TXA2 on glomerular
arterioles and mesangial cells [12]. Our study involved long
term treatment with a TX-synthase inhibitor and initiated at an
early stage of the disease; the question whether similar benefi-
cial effects on renal hemodynamics can be obtained at a late
stage, in the face of a full blown picture of kidney disease, has
been partially addressed in our acute study in 12-month-old
MNS. Four hour infusion of a dose of FCE 22178, completely
inhibiting TXB, formation in whole blood during clotting, did
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not significantly modify RPF or GFR. A vasoconstrictive activ-
ity of endoperoxides accumulating in presence of TX-synthase
inhibition can be excluded by the experiments performed
treating the rats with both FCE 22178 and the PGH2/TXA2
receptor antagonist, BM 13,177.
Therefore, neither TXA2, nor vasodilator prostaglandin (PG)
synthesis (possibly increased by PGH2 rediversion) seem to
acutely modulate renal hemodynamics in already diseased
MNS. Other experimental models, for example, streptozotocin
diabetic rats, characterized by enhanced glomerular production
of TXA2 and PGs [45] associated with hyperfiltration and
proteinuria [46], have recently been reported to get benefit from
TX-synthase inhibition, irrespective of changes in renal hemo-
dynamics [47]. We suggest that TX-synthase inhibition might
ameliorate renal function in chronic studies also by playing a
modulating role on mesangial cell growth. TXA2 and PGs in fact
have been implicated in the regulation of the growth of many
cell types including glomerular cells [48, 49]. It could be
speculated that an altered balance between growth-stimulating
and growth-inhibitory cyclooxygenated products may contrib-
ute, at least partially, to the development and progression of
glomerular lesions in certain experimental models of protein-
uria.
Previous work by one of us has shown that in MNS rats, in
addition to TXA2, glomerular production of prostaglandin
(PG)E2 and PG!2 (prostacyclin) is also increased [28].
Finally, the hyperlipidemia which was evident from the
eighth month of life in control MNS, was dramatically reduced
by FCE 22178. A direct action of the drug on lipid metabolism
can be ruled out on the basis of indirect evidence obtained in a
different rat model of experimental hyperlipidemia where
chronic treatment with FCE 22178 did not modify serum total
cholesterol (unpublished observation). On the other hand, a
complex disorder of plasma lipoproteins with hypertriglyceri-
demia and hypercholesterolemia similar to that found by us in
MNS rats has been described in rats with nephrotic syndrome
induced by puromycin aminonucleoside [50] or by adriamycin
[20], and also in rats with subtotal nephrectomy [51].
These data, taken together, suggest that the nephrotic syn-
drome itself might be the main cause of hyperlipidemia in MNS
rats. Therefore the beneficial effect of FCE 22178 on the lipid
disorder is likely secondary to the normalization of renal
function and the reduction of proteinuria. In conclusion, our
present results indicate that, although many features of the
disease are similar to those of other models of renal damage in
the rat, the MNS glomerulosclerosis is not associated with
systemic hypertension. On the other hand, MNS rats represent
the first, non-immune, genetic model of long lasting proteinuria
and age-related glomerulosclerosis in which enhanced intra-
renal synthesis of TXA2 has been documented and correlated
with functional and structural abnormalities.
The beneficial effects obtained with FCE 22178 suggest that
TX-synthase inhibitors might open new perspectives in the
therapy of chronic renal disease and associated lipid disorders.
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